Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Surgical Oncology
Erschienen in: Indian Journal of Surgical Oncology 2/2016

03.02.2016 | Review Article

Cytoreductive Surgery and Peritonectomy Procedures

verfasst von: Sanket S. Mehta, Aditi Bhatt, Olivier Glehen

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has become widely accepted as an effective method of treating peritoneal metastases (PM) from various cancers. CRS performed with the goal of removing all the macroscopic disease and comprises of peritonectomy procedures and visceral resections. CRS is a technically challenging surgery that requires a considerable amount of skill and appropriate patient selection. This article is a review of the techniques and current recommendations for performing CRS.
Literatur
1.
Lambert LA (2015) Looking up: Recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin 65(4):284–298CrossRefPubMed
2.
Sugarbaker PH (2015) Management of peritoneal metastases - Basic concepts. J BUON 20(Suppl 1):S2–11PubMed
3.
Healy JC, Reznek RH (1998) The peritoneum, mesenteries and omenta: normal anatomy and pathological processes. Eur Radiol 8:886–900CrossRefPubMed
4.
Meyers MA, Oliphant M, Berne AS, Feldberg MA (1987) The peritoneal ligaments and mesenteries: pathways of intraabdominal spread of disease. Radiology 163:593–604CrossRefPubMed
5.
Levy AD, Arnáiz J, Shaw JC, Sobin LH (2008) From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. Radiographics 28:583–607 quiz 621-622CrossRefPubMed
6.
Sheth S, Horton KM, Garland MR, Fishman EK (2003) Mesenteric neoplasms: CT appearances of primary and secondary tumors and differential diagnosis. Radiographics 23:457–473CrossRefPubMed
7.
Oliphant M, Berne AS (1982) Computed tomography of the subperitoneal space: demonstration of direct spread of intraabdominal disease. J Comput Assist Tomogr 6:1127–1137CrossRefPubMed
8.
Karaosmanoglu D, Karcaaltincaba M, Oguz B, Akata D, Ozmen M, Akhan O (2009) CT findings of lymphoma with peritoneal, omental and mesenteric involvement: peritoneal lymphomatosis. Eur J Radiol 71:313–317CrossRefPubMed
9.
10.
11.
12.
Bao P, Bartlett D (2009) Surgical techniques in visceral resection and peritonectomy procedures. Cancer J 15(3):204–211CrossRefPubMed
13.
14.
Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH (2003) Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 22:465–472CrossRefPubMed
15.
Sugarbaker PH (2002) The subpyloric space: an important surgical and radiologic feature in pseudomyxoma peritonei. Eur J Surg Oncol 28:443–446CrossRefPubMed
16.
Sugarbaker P (2013) Cytoreductive surgery using peritonectomy and visceral resections for peritoneal surface malignancy. Transl Gastrointest Cancer 2(2):54–74
17.
Mohamed F, Cecil T, Moran B, Sugarbaker P (2011) A new standard of care for the management of peritoneal surface malignancy. Curr Oncol 18(2):e84–e96CrossRefPubMedPubMedCentral
18.
Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374CrossRefPubMed
19.
20.
Ronnett BM, Shmookler BM, Sugarbaker PH, Kurman RJ (1997) Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol 2:197–226PubMed
21.
Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O (2009) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28(1):63–68CrossRefPubMed
22.
Yan TD, Deraco M, Baratti D, et al. (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–6242CrossRefPubMed
23.
Verwaal VJ, Kusamura S, Baratti D, et al. (2008) The eligibility for local-regional treatment of peritoneal surface malignancy. J Surg Oncol 98:220–223CrossRefPubMed
24.
Yan TD, Morris DL, Kusamura S, et al. (2008) Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy. J Surg Oncol 98:224–227CrossRefPubMed
25.
Coakley FV, Choi PH, Gougoutas CA, et al. (2002) Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 223:495–499CrossRefPubMed
26.
Esquivel J, Chua TC, Stojadinovic A, et al. (2010) Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol 102:565–570CrossRefPubMed
27.
Low RN, Barone RM, Lee MJ (2013) Surveillance MR imaging is superior to serum tumor markers for detecting early tumor recurrence in patients with appendiceal cancer treated with surgical cytoreduction and HIPEC. Ann Surg Oncol 20(4):1074–1081CrossRefPubMed
28.
Torkzad MR, Casta N, Bergman A, Ahlström H, Påhlman L, Mahteme H (2015) Comparison between MRI and CT in prediction of peritoneal carcinomatosis index (PCI) in patients undergoing cytoreductive surgery in relation to the experience of the radiologist. J Surg Oncol 111(6):746–751CrossRefPubMed
29.
Dromain C, Leboulleux S, Auperin A, et al. (2008) Staging of peritoneal carcinomatosis: Enhanced CT vs. PET/CT. Abdom Imaging 33:87–89CrossRefPubMed
30.
Jacquet P, Jelinek JS, Chang D, et al. (1995) Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg 181:530–538PubMed
31.
Yan TD, Haveric N, Carmignani CP, et al. (2005) Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 103:839–849CrossRefPubMed
32.
Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Kluwer Academic Publishers, Boston, pp. 359–374CrossRef
33.
Goéré D, Souadka A, Faron M, Cloutier AS, Viana B, Honoré C, Dumont F, Elias D (2015) Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol 22(9):2958–2964CrossRefPubMed
34.
Coccolini F, Catena F, Glehen O, Yonemura Y, Sugarbaker PH, Piso P, Montori G, Ansaloni L (2015) Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol 41(7):911–919CrossRefPubMed
35.
Bakrin N, JM B, Decullier E, JM C, Msika S, Lorimier G, Abboud K, Meeus P, Ferron G, Quenet F, Marchal F, Gouy S, Morice P, Pomel C, Pocard M, Guyon F, Porcheron J, Glehen O, FROGHI (FRench Oncologic and Gynecologic HIPEC) Group (2013) Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 39(12):1435–1443CrossRefPubMed
36.
Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, et al. (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30(20):2449–2456CrossRefPubMed
37.
Sugarbaker PH (2013) Cytoreductive surgery and perioperative chemotherapy: Textbook and video atlas. Cine-Med Publishing, Connecticut
38.
Sugarbaker PH (1999) Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 43:15–25CrossRef
39.
Glehen O, FN G, Arvieux C, Cotte E, Boutitie F, Mansvelt B, JM B, Lorimier G, Quenet F, Elias D, Association Française de Chirurgie (2010) Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17(9):2370–2377CrossRefPubMed
40.
Glehen O, Mohamed F, Sugarbaker PH (2004) Incomplete Cytoreduction in 174 Patients with Peritoneal Carcinomatosis From Appendiceal Malignancy. Ann Surg 240(2):278–285CrossRefPubMedPubMedCentral
41.
Dayal S, Taflampas P, Riss S, Chandrakumaran K, Cecil TD, Mohamed F, Moran BJ (2013) Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. Dis Colon Rectum 56(12):1366–1372CrossRefPubMed
42.
González-Moreno S, Ortega-Pérez G, González-Bayón L (2009) Indications and patient selection for cytoreductive surgery and perioperative intraperitoneal chemotherapy. J Surg Oncol 100(4):287–292CrossRefPubMed
43.
Passot G, Vaudoyer D, Cotte E, You B, Isaac S, Noël Gilly F, Mohamed F, Glehen O (2012) Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Ann Surg 256(1):125–129CrossRefPubMed
44.
Honoré C, Souadka A, Goéré D, Dumont F, Deschamps F, Elias D (2012) HIPEC for peritoneal carcinomatosis: does an associated urologic procedure increase morbidity? Ann Surg Oncol 19(1):104–109CrossRefPubMed
45.
Glehen O, Beaujard AC, Arvieux C, Huber O, Gilly FN (2002) Peritoneal carcinomatosis. Surgical treatment, peritonectomy and intraperitoneal chemohyperthermia. Gastroenterol Clin Biol 26:210–215PubMed
46.
Elias DM, Ouellet JF (2001) Intraperitoneal chemohyperthermia: rationale, technique, indications, and results. Surg Oncol Clin N Am 10:915–933PubMed
47.
Elias D, Benizri E, Pocard M, Ducreux M, Boige V, Lasser P (2006) Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Surg Oncol 32:632–636CrossRefPubMed
48.
Kianmanesh R, Scaringi S, Sabate JM, Castel B, Pons-Kerjean N, Coffin B, Hay JM, Flamant Y, Msika S (2007) Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg 245:597–603CrossRefPubMedPubMedCentral
49.
Cotte E, Passot G, Gilly F-N, Glehen O (2010) Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol 2(1):31–35CrossRefPubMedPubMedCentral
50.
51.
52.
Zappa L, Sugarbaker PH (2007) Compartment syndrome of the leg associated with lithotomy position for cytoreductive surgery. J Surg Oncol 96:619–623CrossRefPubMed
53.
de Lima VV, Sugarbaker PH (2003) Xiphoidectomy. Gastric Cancer 6:127–129
54.
Vazquez Vde L, Sugarbaker PH (2003) Total anterior parietal peritonectomy. J Surg Oncol 83:261–263CrossRefPubMed
55.
Dagbert F, Passot G, Glehen O, Bakrin N (2015) Glisson capsulectomy for extensive superficial liver involvement in peritoneal carcinomatosis (with video). J Visc Surg 152(5):332–333CrossRefPubMed
56.
Deslauriers N, Olney H, Younan R (2011) Splenectomy revisited in 2011: Impact on hematologic toxicities while performing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Gastrointest Oncol 2(2):61–63PubMedPubMedCentral
57.
Becher RD, Shen P, Stewart JH, Russell G, Bradley JF, Levine EA (2011) Splenectomy ameliorates hematologic toxicity of hyperthermic intraperitoneal chemotherapy. J Gastrointest Oncol 2(2):70–76PubMedPubMedCentral
58.
Sugarbaker PH (2010) Pont hepatique (hepatic bridge), an important anatomic structure in cytoreductive surgery. J Surg Oncol 101:251–252CrossRefPubMed
59.
60.
Bijelic L, Sugarbaker PH (2008) Cytoreduction of the small bowel surfaces. J Surg Oncol 97:176–179CrossRefPubMed
61.
Pathiraja PNJ, Garruto-Campanile R, Tozzi R (2013) Diaphragmatic Diaphragmatic peritonectomy versus full thickness diaphragmatic resection and pleurectomy during cytoreduction in patients with ovarian cancer. Int J Surg Oncol 2013:876150PubMedPubMedCentral
62.
Hertel H, Diebolder H, Herrmann J, Köhler C, Kühne-Heid R, Possover M, Schneider A (2001) Is the decision for colorectal resection justified by histopathologic findings: a prospective study of 100 patients with advanced ovarian cancer. Gynecol Oncol; 83(3):481–484. PMID:11733959
63.
Obermair A, Hagenauer S, Tamandl D, Clayton RD, Nicklin JL, Perrin LC, Ward BG, Crandon AJ (2001) Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol 83(1):115–120CrossRefPubMed
64.
Yildirim Y, Ertas IE, Nayki U, Ulug P, Nayki C, Yilmaz I, Gultekin E, Dogan A, Aykas A, Ulug S, Ozdemir A, Solmaz U (2014) En-bloc pelvic resection with concomitant rectosigmoid colectomy and immediate anastomosis as part of primary cytoreductive surgery for patients with advanced ovarian cancer. Eur J Gynaecol Oncol 35(4):400–407PubMed
65.
Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH, Barakat RR, Chi DS (2005) Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 99(3):608–614CrossRefPubMed
66.
Sonnendecker EW, Beale PG (1989) Rectosigmoid resection without colostomy during primary cytoreductive surgery for ovarian carcinoma. Int Surg 74(1):10–12PubMed
67.
Sugarbaker PH (2015) Avoiding Diverting Ileostomy in Patients Requiring Complete Pelvic Peritonectomy. Ann Surg Oncol 2015
68.
Sugarbaker PH (2002) Cytoreduction including total gastrectomy for pseudomyxoma peritonei. Br J Surg 89(2):208–212CrossRefPubMed
69.
Piso P, Slowik P, Popp F, Dahlke MH, Glockzin G, Schlitt HJ (2009) Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 16(8):2188–2194CrossRefPubMed
70.
Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR (2009) Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol 100(4):321–328. doi:10.​1002/​jso.​21388 CrossRefPubMed
71.
Foster JM, Gupta PK, Carreau JH, Grotz TE, Blas JV, Gatalica Z, Nath S, Loggie BW (2012) Right hemicolectomy is not routinely indicated in pseudomyxoma peritonei. Am Surg 78(2):171–177PubMed
72.
Doud AN, Randle RW, Clark CJ, Levine EA, Swett KR, Shen P, Stewart JH, Votanopoulos KI (2015) Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2(5):1645–1650CrossRef
73.
Schwarz L, Votanopoulos K, Morris D, Yonemura Y, Deraco M, Piso P, Moran B, Levine EA, Tuech JJ (2016) Is the Combination of Distal Pancreatectomy and Cytoreductive Surgery With HIPEC Reasonable?: Results of an International Multicenter Study. Ann Surg 263(2):369–375CrossRefPubMed
74.
Mahdi H, Rose PG, Gonzalez S, DeBernardo R, Knight J, Michener C, Moselmi-Kebria M (2015) Postoperative Complications After Distal Pancreatectomy Performed During Cytoreductive Surgery for Gynecologic Malignancies. Int J Gynecol Cancer 25(6):1128–1133CrossRefPubMed
75.
Bacalbasa N, Dima S, Brasoveanu VDavid L, et al. (2015) Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit. World J Surg Oncol 13:235CrossRefPubMedPubMedCentral
76.
Gasparri ML, Grandi G, Bolla D, Gloor B, Imboden S, Panici PB, Mueller MD, Papadia A (2015) Hepatic resection during cytoreductive surgery for primary or recurrent ovarian cancer. J Cancer Res Clin Oncol 1–12
77.
Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, et al. (2003) Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 10:863–869CrossRefPubMed
78.
Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FAN (2004) Toxicity of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol 85:61–67CrossRefPubMed
79.
Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, et al. (2006) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 106:1144–1153CrossRefPubMed
80.
Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, et al. (1999) Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 6:790–796CrossRefPubMed
81.
Franko J, Gusani NJ, Holtzman MP, Ahrendt SA, Jones HL, HJ Z 3rd, DL B (2008) Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol 15(11):3065–3072CrossRefPubMed
Metadaten
Titel
Cytoreductive Surgery and Peritonectomy Procedures
verfasst von
Sanket S. Mehta
Aditi Bhatt
Olivier Glehen
Publikationsdatum
03.02.2016
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 2/2016
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-016-0505-5

Weitere Artikel der Ausgabe 2/2016

Indian Journal of Surgical Oncology 2/2016 Zur Ausgabe

DESK OF THE EDITOR

Desk of the Editor

Preface

Preface

Review Article

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

Review Article

Safety considerations for Health care Workers involved in Cytoreductive Surgery and Perioperative chemotherapy

Review Article

Intensive Care Management of Patient After Cytoreductive Surgery and HIPEC - A Concise Review

Review Article

Diagnostic Laparoscopy in the Pre-operative Assessment of Patients Undergoing Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancies

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.